FDA Grants Orphan Drug Designation to Sanofi’s Rare Disease Drug Rilzabrutinib for wAIHA & IgG4-RD
Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...
Raymond James Financial Inc. purchased a new position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the fourth quarter, ...
During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback